Welcome to our dedicated page for Bayer Aktien news (Ticker: BAYRY), a resource for investors and traders seeking the latest updates and insights on Bayer Aktien stock.
BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
As of April 26, 2021, over 40,000 claims regarding non-Hodgkin's lymphoma linked to Bayer's Roundup herbicide remain unsettled. Plaintiffs argue that the proposed settlement is unfair and favor jury trials for justice. The Fears Nachawati Law Firm aims to discard the settlement, which permits Bayer to negotiate with law firms individually, potentially leading to lower compensation for remaining cancer claims. Glyphosate, the active ingredient in Roundup, has been associated with cancer, resulting in multimillion-dollar verdicts against Bayer in previous trials.
On March 5, 2021, a federal judge was urged by cancer victims to reject a proposed settlement regarding Roundup lawsuits against Bayer AG (OTCMKTS: BAYRY). The motion highlights concerns over existing settlements favoring certain plaintiffs while excluding others diagnosed post-February 3, 2021. Critics argue this settlement protects Bayer and undermines due-process rights, potentially limiting compensation for future claimants. The ongoing multidistrict litigation focuses on cancer claims related to glyphosate exposure, with significant implications for those affected by Roundup.